Viewing nowCombinationPamika Tablets 5/20 mg
Olmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
HanKook Pharma Co., Ltd.

MFDS item code 201405513 · Approved 2014.11.25 · Insurance code 653005500
Treatment of essential hypertension not controlled by monotherapy
This medication is used for the treatment of patients with essential hypertension whose blood pressure is not adequately controlled by Amlodipine or Olmesartan Medoxomil alone. Essential hypertension can increase the risk of cardiovascular diseases, so these medications help to effectively lower blood pressure and improve health.
Administer 1 tablet of this medicine once daily with water, with or without food. It is recommended to take it at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood-pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. This medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine must not be administered to patients with severe hepatic impairment. (See section 2, Patients who must not be administered this medicine, under Precautions for Use.) ○ Older adults: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults.
The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established.
This drug may cause severe harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. This drug should not be used by individuals allergic to its main ingredients or similar substances, women who are pregnant or breastfeeding, patients with severe liver impairment or aortic stenosis, patients undergoing dialysis, patients in a state of shock, and specific diabetic patients. In patients with low blood pressure caused by fluid or electrolyte depletion, symptoms of hypotension may occur, so administration should be done with careful observation of the condition. In patients with aortic stenosis or heart disease, there is a risk of severe hypotension due to rapid blood vessel dilation, so caution is required. Patients with impaired kidney function or liver disease should use this drug cautiously as it may affect kidney or liver function. When taking this medication, side effects such as dizziness, headache, drowsiness, and hypotension may occur; therefore, caution should be exercised when driving or operating machinery. It may pose risks to the fetus during pregnancy, so those planning to become pregnant or who are pregnant should consult a doctor. Breastfeeding women should discontinue breastfeeding or the medication, as it can be transmitted through breast milk and may affect the baby. Children under 18 years of age should not use this medication as safety and effectiveness have not been established. Elderly patients should start at a lower dosage, considering potential declines in kidney and liver function, and their condition should be carefully observed. In cases of overdose, severe hypotension and cardiovascular issues may occur, and immediate medical attention is required. This drug is sensitive to moisture, heat, and light, so it should be stored in a cool, dry place out of reach of children. Additionally, there may be interactions when taken with other medications, so inform a doctor or pharmacist of any other drugs being taken.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to prevent exposure to air or moisture. It is also advisable to avoid extremely hot or cold environments, keeping it at room temperature between 1 degree and 30 degrees Celsius.
White round film-coated tablets
28 tablets (14 tablets/PTP x2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
HanKook Pharma Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.